9.76

0.10% -0.010

After Hours: 9.76

Neumora Therapeutics Inc (NMRA)

Overview News Price History Option Chain Financials Why NMRA Down? Discussions Forecast

Neumora Therapeutics Inc stock is traded at $9.76, with a volume of 538.26K. It is down -0.10% in the last 24 hours and down -20.46% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Previous Close:

$9.77

Open:

$9.74

24h Volume:

538.26K

Relative Volume:

0.52

Market Cap:

$1.59B

Revenue:

Net Income/Loss:

$-274.18M

P/E Ratio:

-5.6804

EPS:

-1.7182

Net Cash Flow:

$-198.33M

1W Performance:

-0.31%

1M Performance:

-20.46%

6M Performance:

+6.43%

1Y Performance:

-18.05%

1-Day Range:

$9.64

$9.97

1-Week Range:

$9.50

$10.13

52-Week Range:

$8.33

$21.00

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name

Neumora Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(857) 760-0900

Address

490 ARSENAL WAY, SUITE 200, WATERTOWN

Employee

109

Twitter

Next Earnings Date

Latest SEC Filings

NMRA's Discussions on Twitter

Compare NMRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NMRA Neumora Therapeutics Inc	9.76	1.59B	0	-274.18M	-198.33M	-1.7182
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jul-22-24	Initiated	Needham	Buy
Jul-08-24	Initiated	Mizuho	Outperform
Dec-12-23	Initiated	Deutsche Bank	Hold
Oct-10-23	Initiated	BofA Securities	Buy
Oct-10-23	Initiated	Guggenheim	Buy
Oct-10-23	Initiated	JP Morgan	Overweight
Oct-10-23	Initiated	RBC Capital Mkts	Outperform
Oct-10-23	Initiated	Stifel	Buy
Oct-10-23	Initiated	William Blair	Outperform

View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

Nov 27, 2024

Head-To-Head Analysis: Neumora Therapeutics (NMRA) vs. Its Competitors - Defense World

Nov 27, 2024

Nov 26, 2024

Neumora Therapeutics' SWOT analysis: stock poised for growth amid MDD trial - Investing.com Canada

Nov 26, 2024

Nov 25, 2024

Neumora Therapeutics’ (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - Defense World

Nov 25, 2024

Nov 23, 2024

Neumora Therapeutics' (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat

Nov 23, 2024

Contrasting Neumora Therapeutics (NMRA) and Its Competitors - Defense World

Nov 23, 2024

Nov 21, 2024

Head-To-Head Survey: Neumora Therapeutics (NMRA) vs. Its Rivals - Defense World

Nov 21, 2024

Nov 20, 2024